Bridge Pharma, Inc.
Records under this name other than the patents Bridge Pharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,778,971 | Medicinal Treatment of Dermal Diseases in Companion Animals Lapsed on the fee record Ended Jul 15, 2026 · High confidence | Lapsed on the fee record | Ended Jul 15, 2026 | High confidence |
| US 8,557,846 | Medicinal Treatment of Dermal Diseases in Dogs Lapsed on the fee record Ended Oct 15, 2025 · Medium confidence | Lapsed on the fee record | Ended Oct 15, 2025 | Medium confidence |
| US 9,694,003 | Formulations and methods for treating high intraocular pressure Lapsed on the fee record Ended Jul 4, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jul 4, 2025 | From the USPTO record |
| US 8,071,653 | Use of RR/SR-ractopamine Lapsed on the fee record Ended Dec 6, 2023 · From the USPTO record | Lapsed on the fee record | Ended Dec 6, 2023 | From the USPTO record |
| US 7,985,775 | Methods of accelerating muscle growth, decreasing fat deposits and improving feed efficiency in livestock animals Lapsed on the fee record Ended Jul 26, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jul 26, 2023 | From the USPTO record |
| US 8,969,385 | Ocular formulations of norketotifen Lapsed on the fee record Ended Mar 3, 2023 · From the USPTO record | Lapsed on the fee record | Ended Mar 3, 2023 | From the USPTO record |
| US 8,765,787 | Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen Lapsed on the fee record Ended Jul 1, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jul 1, 2022 | From the USPTO record |
| US 8,741,930 | Treating xerophthalmia with norketotifen Lapsed on the fee record Ended Jun 3, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jun 3, 2022 | From the USPTO record |
| US 7,723,392 | Use of RR/SR-ractopamine Lapsed on the fee record Ended May 25, 2022 · From the USPTO record | Lapsed on the fee record | Ended May 25, 2022 | From the USPTO record |
| US 8,445,542 | Methods of accelerating muscle growth, decreasing fat deposits and improving feed efficiency in livestock animals Lapsed on the fee record Ended May 21, 2021 · From the USPTO record | Lapsed on the fee record | Ended May 21, 2021 | From the USPTO record |